As an illustration of the prognostic value of RAS mutation in the serum, we estimated the 3‐year OS of a standard patient (stage II disease, highly differentiated tumor, no perforation of peritoneum, no neural‐ or vascular involvement, and no BRAF mutation) based on the multivariate Cox regression analysis. The gene discussed is BRAF; the disease is neoplasm.